AbbVie signed an MFN (Most Favored Nation) drug pricing agreement with the Trump administration, which sets the lowest prices available in comparable countries.[1][3] Under the agreement, AbbVie will offer drugs such as Combigan for glaucoma, Synthroid for thyroid, Humira for rheumatoid arthritis and Alphagan for glaucoma at MFN prices to Medicaid and directly to consumers through the TrumpRx platform.[1][3] It will sell some other drugs at significant discounts compared to list prices.[1] The company has committed to investing $100 billion in research, development and construction in the US over the next decade.[3] The agreement lasts for three years and grants AbbVie an exemption from tariffs and future price regulations.[3] AbbVie is one of 16 major pharmaceutical companies that have entered into such agreements.[3] According to the head of AbbVie, Robert A. Michael, it is an effort to improve the accessibility of medicines for patients.[3]